Last reviewed · How we verify

NCT03105024

Self-efficacy Enhancement and Exposure Therapy

Completed NA Last updated 11 April 2018
What this trial tests

NA trial testing Self-efficacy enhancement in Specific Phobia in 71 participants. Completed in 29 November 2017.

Timeline
22 March 2017
Primary endpoint
29 November 2017
29 November 2017

Quick facts

Lead sponsorRuhr University of Bochum
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment71
Start date22 March 2017
Primary completion29 November 2017
Estimated completion29 November 2017
Sites1 location across Germany

Drugs / interventions tested

Conditions studied

Sponsor

Ruhr University of Bochum

Who can join

Adults 18 to 38, any sex, with Specific Phobia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Self-efficacy refers to the perceived belief to cope effectively, by personal efforts, with challenging situations and problems (Bandura, 1977). Basic research has shown that increases in perceived self-efficacy can enhance the extinction of fear (Zlomuzica et al., 2015). This study is aimed at translating these findings into a useful clinical application to augment exposure-based treatment outcome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Specific Phobia

Currently open trials in the same condition.

Other Ruhr University of Bochum trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03105024.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing